findmyKOL

Bradley Monk, MD

Enriched profile

Medical Director, Late-Phase Clinical Research · Florida Cancer Specialists & Research Institute

ORCID↗NPI↗
✓ Full profile
Region🇺🇸 West Palm Beach, FL · Southeast · United StatesSpecialtyGynecologic OncologyFocusOvarian cancer diagnosis and treatment+4
Active KOLfindmyKOL type: NationalLatest publication2026Online presenceverified 2026Payments2021–2025NIH fundingNone on fileWhy? →

Bradley Monk is Medical Director, Late-Phase Clinical Research at Florida Cancer Specialists & Research Institute. OpenAlex indexes 1,001 publications with 45,442 citations (h-index 94); ClinicalTrials.gov lists 18 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Gynecologic Oncology profiles in the findmyKOL directory.

Data verified 17 Oct 2026

Overview

Updated 18 Oct 2026

Bradley J. Monk, MD, is Medical Director, Late-Phase Clinical Research at Florida Cancer Specialists & Research Institute (West Palm Beach, Good Samaritan/Flagler). The public record shows 1,001 publications with 45,442 citations (h-index 94), centered on Ovarian cancer diagnosis and treatment, Endometrial and Cervical Cancer Treatments, PARP inhibition in cancer therapy. It also documents an investigator role on 18 registered clinical trials, industry payments reported by 58 companies.

  • Most recent indexed publication: 2026 · JCO precision oncology
  • Top research focus: Ovarian cancer diagnosis and treatment
  • 18 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 58 companies

Generated from the cited public record · current as of 18 Oct 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Ovarian / Gynecologic Cancer13 trialsUterine Cervical Neoplasms5 trialsFallopian Tube Neoplasms4 trialsCarcinoma, Squamous Cell2 trialsBrenner Tumor2 trialsCarcinoma, Endometrioid2 trialsCarcinoma, Adenosquamous1 trialSarcoma1 trialComa1 trialCarcinoma, Transitional Cell1 trialAdenocarcinoma, Clear Cell1 trialAdenocarcinoma, Mucinous1 trialCysts1 trialCystadenocarcinoma, Serous1 trialCystadenocarcinoma, Mucinous1 trialCystadenocarcinoma1 trialCarcinoma, Ovarian Epithelial1 trialLymphoma1 trialLymphoma, Follicular1 trialNeoplasm Metastasis1 trialPeritoneal Neoplasms1 trial

Research focus

OpenAlex concept fingerprint
Ovarian cancer diagnosis and treatmentEndometrial and Cervical Cancer TreatmentsPARP inhibition in cancer therapyCervical Cancer and HPV ResearchCancer Immunotherapy and Biomarkers

Drugs & molecules

across trials, industry payments and publications
Keytrudageneric · PembrolizumabClinical trials1Industry payments56Publications6Zejulageneric · NiraparibClinical trials—Industry payments185Publications7Tivdakgeneric · TisotumabClinical trials—Industry payments173Publications2Lynparzageneric · OlaparibClinical trials—Industry payments92Publications1Jemperligeneric · DostarlimabClinical trials—Industry payments79Publications1Elaheregeneric · Mirvetuximab soravtansineClinical trials—Industry payments62Publications2Lenvimageneric · LenvatinibClinical trials—Industry payments41Publications1Enhertugeneric · TrastuzumabClinical trials—Industry payments14Publications1BevacizumabClinical trials3Industry payments—Publications11Xpoviogeneric · SelinexorClinical trials—Industry payments12Publications2PaclitaxelClinical trials6Industry payments—Publications6Rubracageneric · RucaparibClinical trials—Industry payments9Publications2

Works with

trial sponsors and companies reporting payments
Eli Lilly and CompanyClinical trials1Industry payments2GlaxoSmithKline, LLC.Clinical trials—Industry payments296Merck Sharp & Dohme LLCClinical trials—Industry payments130AstraZeneca Pharmaceuticals LPClinical trials—Industry payments123Genmab U.S., Inc.Clinical trials—Industry payments121Seagen Inc.Clinical trials—Industry payments86Myriad Genetic Laboratories, Inc.Clinical trials—Industry payments50Abbvie Inc.Clinical trials—Industry payments44Eisai Inc.Clinical trials—Industry payments40Regeneron Pharmaceuticals, Inc.Clinical trials—Industry payments28ImmunoGen, Inc.Clinical trials—Industry payments22Pfizer Inc.Clinical trials—Industry payments18Clovis Oncology, Inc.Clinical trials—Industry payments16Janssen Biotech, Inc.Clinical trials—Industry payments16AstraZeneca UK LimitedClinical trials—Industry payments14Corcept TherapeuticsClinical trials—Industry payments14Daiichi Sankyo Inc.Clinical trials—Industry payments13Takeda Pharmaceuticals U.S.A., Inc.Clinical trials—Industry payments13Karyopharm Therapeutics Inc.Clinical trials—Industry payments12Merck Sharp & Dohme CorporationClinical trials—Industry payments12Aadi Bioscience, Inc.Clinical trials—Industry payments9BioNTech SEClinical trials—Industry payments9Incyte CorporationClinical trials—Industry payments8Novocure Inc.Clinical trials—Industry payments8Acrotech Biopharma Inc.Clinical trials—Industry payments5Gynecologic Oncology GroupClinical trials4Industry payments—Novocure GmbHClinical trials—Industry payments4Amgen Inc.Clinical trials—Industry payments3Array Biopharma IncClinical trials—Industry payments3Bayer HealthCare Pharmaceuticals Inc.Clinical trials—Industry payments3

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
1,001publications

Distinct works indexed by OpenAlex, matched via ORCID; 41 in PubMed.

45,442citations

Total citations across indexed works.

94h-index

Hirsch index (OpenAlex). i10-index 422.

Clinical & industry

trials, payments and federal funding
18clinical trials

Investigator role on registered studies.

View trials ↓
58companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
0NIH grants

Federally funded research awards.

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 18 Oct 2026

Listed as an investigator on 18 registered studies on ClinicalTrials.gov. The most recent:

All 18 trial records: search, sort and filter.Explore →

Industry payments

Updated 18 Oct 2026

58 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

All 118 payment records: search, sort and filter.Explore →
View the CMS Open Payments record ↗

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    100%
    Aromatase Inhibitor100%
    Letrozole100%
    Part D<11 patients
Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →

Publications

Updated 18 Oct 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

All 41 publications: search, sort and filter.Explore →

Most-cited works

by citation count (OpenAlex)
  1. 01
    Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
    2,460 citations2016
    doi.org ↗
  2. 02
    Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
    2,386 citations2011
    doi.org ↗
  3. 03
    Concurrent Chemotherapy and Pelvic Radiation Therapy Compared With Pelvic Radiation Therapy Alone as Adjuvant Therapy After Radical Surgery in High-Risk Early-Stage Cancer of the Cervix
    2,326 citations2000
    doi.org ↗
  4. 04
    Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
    2,265 citations2019
    doi.org ↗
  5. 05
    Improved Survival with Bevacizumab in Advanced Cervical Cancer
    1,502 citations2014
    doi.org ↗
All 1,001 cited works: search, sort and filter.Explore →

Network

Updated 18 Oct 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Robert L. Coleman166Krishnansu S. Tewari156Ignace Vergote132David M. O’Malley119Mansoor Raza Mirza117Thomas J. Herzog105Kathleen N. Moore101Robert A. Burger99Antonio González-Martı́n98Domenica Lorusso91Bhavana Pothuri84Dana M. Chase79Ana Oaknin79John K. Chan77Nicoletta Colombo63Amit M. Oza61Whitney A. Spannuth Graybill61Brian M. Slomovitz60Leslie M. Randall55Jalid Sehouli54Susana Banerjee51Carol Aghajanian47Thomas J. Herzog47David Cibula46Joan L. Walker45Lari Wenzel42Michael W. Sill42Keiichi Fujiwara41Isabelle Ray‐Coquard41Lisa M. Landrum41Mario M. Leitão40Larry J. Copeland40Richard T. Penson40Michael J. Birrer38Robert S. Mannel37Sandro Pignata35Heather A. Lankes34Christian Marth34Ramez N. Eskander33John Farley33

Online presence

Updated 18 Oct 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/bradley-monk-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
  • LinkedIn

    linkedin.com/in/bradley-j-monk-md-4879a7155

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗

Mentions by others

where others cite or feature them
  • Other

    videopodcast.researchtopractice.com/ovarian-cancer-bradley-j-monk-md

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →videopodcast.researchtopractice.com ↗
  • Other

    emjreviews.com/oncology/congress-review/esgo-2025-insights-an-interview-with-bradley-monk

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →emjreviews.com ↗
  • Facebook

    facebook.com/FloridaCancerSpecialists/posts/were-proud-to-share-that-dr-bradley-monk-fcs-board-certified-gynecologic-oncolog/1389543439838593

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →facebook.com ↗
  • LinkedIn

    linkedin.com/posts/lucio-n-gordan-md-79270b230_fcs-welcomes-gynecologic-oncologist-bradley-activity-7148450113353379841-r_X5

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗
  • LinkedIn

    linkedin.com/posts/natewalcker_bradley-monk-md-will-join-florida-cancer-activity-7117583999010566147-OVZB

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗
  • Spotify

    open.spotify.com/episode/2bVgrF9niIAzvCnFtH9vUs

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →open.spotify.com ↗

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 18 Oct 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • Fellowship

    Gynecologic Oncology, University of California, Irvine

    1995
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →media.mycme.com ↗
  • Residency

    Obstetrics and Gynecology, University of California, Los Angeles

    1992
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →media.mycme.com ↗
  • M.D.

    University of Arizona College of Medicine–Tucson

    1988
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →media.mycme.com ↗
  • B.S. in Premedical Zoology

    Brigham Young University

    1982
    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →en.wikipedia.org ↗
  • Fellowship

    Gynecologic Oncology, MD Anderson Cancer Center, Houston

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →flcancer.com ↗
  • Fellowship

    Medical Genetics, National Institutes of Health, Bethesda

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →flcancer.com ↗
  • Board-certified

    Gynecologic Oncology (FACOG, FACS)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →flcancer.com ↗

Editorial & leadership roles

journal and society appointments
  • Prior Chair

    Gynecologic Cancer Committee, US Oncology Research

    2022
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →media.mycme.com ↗
  • Cervical Cancer Sub-Committee Chair

    NRG Oncology (11 years)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →media.mycme.com ↗
  • Prior Chair

    Cervical Cancer Committee, Gynecologic Cancer Intergroup

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →media.mycme.com ↗
  • Fellow

    American College of Surgeons

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →media.mycme.com ↗
  • Fellow

    American College of Obstetricians and Gynecologists

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →media.mycme.com ↗
  • Fellow

    American Society for Colposcopy and Cervical Pathology

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →media.mycme.com ↗
  • Active member

    Society of Gynecologic Oncology, International Gynecologic Cancer Society, American Society of Clinical Oncology

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →media.mycme.com ↗

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution
  • Director

    GOG-Partners

    2010
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →media.mycme.com ↗
  • Prior: Associate Professor

    Division of Gynecologic Oncology, Chao Family Comprehensive Cancer Center, UC Irvine Medical Center (1998-2010); Director of Research, Dept. of OB/GYN

    2010
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →media.mycme.com ↗
  • Prior: Director of Gynecologic Oncology

    Texas Tech University Health Sciences Center, Lubbock

    1995
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →media.mycme.com ↗
  • Vice President and Member

    Board of Directors, GOG-Foundation

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →media.mycme.com ↗
  • Prior: Director and Principal Investigator

    Virginia G. Piper Cancer Center, HonorHealth, Scottsdale, AZ; Site Research Leader, Sarah Cannon Research Institute

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →media.mycme.com ↗
  • Prior: Professor (clinical scholar track)

    Division of Gynecologic Oncology, University of Arizona College of Medicine–Phoenix, and Director/Professor, Division of Gynecologic Oncology …

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →media.mycme.com ↗

Media & interviews

press, podcasts and appearances
  • Regular contributing author/interview subject

    OncLive

    2026
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
  • Interview

    European Medical Journal (EMJ), ESGO 2025 Insights

    2025
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →emjreviews.com ↗
  • Video interview

    ASCO Post, cervical cancer findings on pembrolizumab plus chemotherapy

    2023
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗
  • Interview guest

    Gynecologic Oncology Update podcast (Research To Practice/Apple Podcasts), real-world ovarian cancer case discussions

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →podcasts.apple.com ↗
  • Featured expert

    PeerView Oncology & Hematology CME/CNE/CPE Video Podcast (immunotherapy in gynecologic cancers)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →podcasts.apple.com ↗

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.